Literature DB >> 33963896

Puerarin protects cardiomyocytes from ischemia-reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy.

Yanhui Han1, Honglei Wang2, Yan Wang3, Pingshuan Dong2, Jingjing Jia2, Shaohui Yang2.   

Abstract

This study analyzed the roles of puerarin and LncRNA ANRIL in myocardial ischemia-reperfusion injury. Hypoxia/reperfusion (H/R) model was established with H9C2 cells. Effects of puerarin of gradient concentrations on cardiomyocytes at different time points of hypoxia and reoxygenation were detected by quantitative real-time polymerase chain reaction (qRT-PCR), cell counting kit-8 (CCK-8), and microscope observation. Effects of puerarin on cardiomyocyte viability, ANRIL expression, contents of lactate dehydrogenase (LDH) and malondialdehyde (MDA), apoptosis, and expressions of autophagy-related genes after H/R injury were determined by CCK-8, quantitative real-time polymerase chain reaction (qRT-PCR), ELISA, flow cytometry, and Western blot, respectively. After cell transfection, the effects of overexpressed and knockdown of ANRIL on cardiomyocytes and H/R-injured cardiomyocytes were examined by rescue experiments. The ischemia-reperfusion (I/R)-injured rat model was established to examine the protective effect of puerarin in vivo. Prolonged hypoxia downregulated ANRIL expression in cardiomyocytes and reduced cardiomyocyte viability. Prolonged reoxygenation increased apoptosis. Both cardiomyocyte viability and ANRIL expression showed a dose-dependent relationship with puerarin. Puerarin reversed the effects of H/R injury on cardiomyocyte viability, ANRIL expression, contents of LDH and MDA, apoptosis, and expressions of autophagy-related genes. Overexpression and knockdown of ANRIL regulated the functions of cardiomyocytes and the expressions of autophagy-related genes. Puerarin reversed the effects of knockdown of ANRIL on H/R-injured cells. The results of In vivo experiments confirmed that puerarin protected myocardial tissues by up-regulating ANRIL and inhibiting autophagy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Autophagy; Cardiomyocyte; Ischemia/reperfusion injury; LncRNA ANRIL; Puerarin

Mesh:

Substances:

Year:  2021        PMID: 33963896     DOI: 10.1007/s00441-021-03463-2

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  9 in total

1.  Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog.

Authors:  R B JENNINGS; H M SOMMERS; G A SMYTH; H A FLACK; H LINN
Journal:  Arch Pathol       Date:  1960-07

2.  Distribution kinetics of puerarin in rat hippocampus after acute local cerebral ischemia.

Authors:  Hui Kong; Guiliang Zhang; Jinjun Cheng; Rongfeng Shi; Meiling Zhang; Peng Cao; Yan Zhao; Huihua Qu; Qingguo Wang
Journal:  J Pharm Biomed Anal       Date:  2018-10-25       Impact factor: 3.935

Review 3.  The role of the autophagy in myocardial ischemia/reperfusion injury.

Authors:  Sai Ma; Yabin Wang; Yundai Chen; Feng Cao
Journal:  Biochim Biophys Acta       Date:  2014-05-21

4.  Reperfusion of the ischemic myocardium.

Authors:  D J Hearse
Journal:  J Mol Cell Cardiol       Date:  1977-08       Impact factor: 5.000

5.  Puerarin attenuates myocardial hypoxia/reoxygenation injury by inhibiting autophagy via the Akt signaling pathway.

Authors:  Huixiong Tang; Xudong Song; Yuanna Ling; Xianbao Wang; Pingzhen Yang; Tao Luo; Aihua Chen
Journal:  Mol Med Rep       Date:  2017-04-03       Impact factor: 2.952

Review 6.  Psychological Stress, Inflammation, and Coronary Heart Disease.

Authors:  Petra H Wirtz; Roland von Känel
Journal:  Curr Cardiol Rep       Date:  2017-09-20       Impact factor: 2.931

Review 7.  Myocardial protection from ischemia-reperfusion injury post coronary revascularization.

Authors:  Andrew Binder; Asghar Ali; Raveen Chawla; Hammad A Aziz; Antonio Abbate; Ion S Jovin
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-07-22

Review 8.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

9.  Changing trends in the prevalence of coronary heart disease.

Authors:  M Sriharibabu
Journal:  Indian Heart J       Date:  2016-04-28
  9 in total
  6 in total

Review 1.  The potentials of distinct functions of autophagy to be targeted for attenuation of myocardial ischemia/reperfusion injury in preclinical studies: an up-to-date review.

Authors:  Behnaz Mokhtari; Reza Badalzadeh
Journal:  J Physiol Biochem       Date:  2021-06-26       Impact factor: 4.158

2.  Puerarin prevents calcium oxalate crystal-induced renal epithelial cell autophagy by activating the SIRT1-mediated signaling pathway.

Authors:  Guan-Hua Jing; Ya-Dong Liu; Jian-Nan Liu; Yin-Shan Jin; Shi-Liang Yu; Rui-Hua An
Journal:  Urolithiasis       Date:  2022-08-01       Impact factor: 2.861

Review 3.  The Regulatory Role of Non-coding RNA in Autophagy in Myocardial Ischemia-Reperfusion Injury.

Authors:  Dan Wang; Zhenchao Niu; Xiaolong Wang
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

4.  Traditional Chinese medicine injections with activating blood circulation, equivalent effect of anticoagulation or antiplatelet, for acute myocardial infarction: A protocol for the systematic review and meta-analysis of randomized clinical trials.

Authors:  Xiang Li; Yan Lou; Ju-Ju Shang; Hong-Xu Liu; Jia-Ping Chen; Hui-Wen Zhou
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

Review 5.  Molecular mechanisms of isoflavone puerarin against cardiovascular diseases: What we know and where we go.

Authors:  Weida Qin; Jianghong Guo; Wenfeng Gou; Shaohua Wu; Na Guo; Yuping Zhao; Wenbin Hou
Journal:  Chin Herb Med       Date:  2022-03-23

Review 6.  Puerarin: A protective drug against ischemia-reperfusion injury.

Authors:  Minglang Gao; Ziyao Zhang; Kai Lai; Yu Deng; Chuanbing Zhao; Zilong Lu; Qing Geng
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.